Descendants of survivors helped researchers identify 279 deportees and tell their stories. ‘We give previously faceless ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best wide moat stocks to invest in. Russell Investments continues to monitor and ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines.

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. The company’s shares closed yesterday at $96.95.

Gilead Sciences, Inc. (NASDAQ:GILD) is still seeing strong product revenue growth regarding its Covid-19 anti-viral drug Veklury [remdesivir]. This is because in the company's Q3 of 2024 financial ...

you should consider Gilead Sciences (GILD). This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat. This HIV and hepatitis C ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on ...